Histone Deacetylase 3 SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98 Pipeline Review, H2 2018
Summary
Histone Deacetylase 3 SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98 pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Histone Deacetylase 3 Pipeline Review, H2 2018, outlays comprehensive information on the Histone Deacetylase 3 SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.
Histone Deacetylase 3 SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98 Histone deacetylase 3 is an enzyme encoded by the HDAC3 gene. Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. It participates in the regulation of transcription through its binding with the zincfinger transcription factor YY1. This protein can also downregulate p53 function and thus modulate cell growth and apoptosis. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 4, 5 and 1 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Dermatology, Gastrointestinal, Genetic Disorders, Infectious Disease, Musculoskeletal Disorders and Undisclosed which include indications Breast Cancer, Follicular Lymphoma, NonSmall Cell Lung Cancer, Hodgkin Lymphoma BCell Hodgkin Lymphoma, Relapsed Acute Myeloid Leukemia, BCell NonHodgkin Lymphoma, Colon Cancer, Diffuse Large BCell Lymphoma, Epithelial Ovarian Cancer, Lymphoma, Mantle Cell Lymphoma, Melanoma, Metastatic Renal Cell Carcinoma, Mycosis Fungoides, NonHodgkin Lymphoma, Prostate Cancer, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Acid Sphingomyelinase Deficiency NiemannPick Disease Type C, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Adenoid Cystic Carcinoma ACC, Alopecia, Anaplastic Large Cell Lymphoma ALCL, Anaplastic Thyroid Cancer, Angioimmunoblastic TCell Lymphoma AITL/Immunoblastic Lymphadenopathy, Basal Cell Carcinoma Basal Cell Epithelioma, Bile Duct Cancer Cholangiocarcinoma, Bladder Cancer, Bone Disorders, Burkitt Lymphoma, Central Nervous System CNS Tumor, CNS Lymphoma, Cutaneous TCell Lymphoma, Drug Addiction, Endometrial Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme GBM, Glioma, Gliosarcoma, Human Immunodeficiency Virus HIV Infections AIDS, Liver Cancer, Liver Fibrosis, Lung Adenocarcinoma, Lung Cancer, Marginal Zone Bcell Lymphoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Uveal Melanoma, Multiple Myeloma Kahler Disease, Myelodysplastic Syndrome, Natural Killer Cell Lymphomas, Neuroblastoma, Neurodegenerative Diseases, Neuroendocrine Cancer, NUT Midline Carcinoma NMC or Nuclear Protein in Testis Midline Carcinoma, Papillary Thyroid Cancer, Peripheral TCell Lymphomas PTCL, Peritoneal Cancer, PostTraumatic Stress Disorder PTSD, Recurrent Glioblastoma Multiforme GBM, Refractory Chronic Lymphocytic Leukemia CLL, Relapsed Chronic Lymphocytic Leukemia CLL, Renal Cell Carcinoma, Soft Tissue Sarcoma, Thyroid Cancer and Unspecified.
Furthermore, this report also reviews key players involved in Histone Deacetylase 3 SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98 targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape for Histone Deacetylase 3 SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98
The report reviews Histone Deacetylase 3 SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources
The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities
The report reviews key players involved in Histone Deacetylase 3 SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98 targeted therapeutics and enlists all their major and minor projects
The report assesses Histone Deacetylase 3 SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news and deals related to Histone Deacetylase 3 SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98 targeted therapeutics
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies
Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage
Identify and understand the targeted therapy areas and indications for Histone Deacetylase 3 SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98
Identify the use of drugs for target identification and drug repurposing
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Histone Deacetylase 3 SMAP45 or RPD3 2 or HDAC3 or EC 3.5.1.98 development landscape
Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope